Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$8.65-2.8%$9.14$0.06▼$14.93$6.61M0.94566,464 shs9,760 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%-3.15%-2.41%-27.06%-76.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.5917 of 5 stars3.50.00.00.01.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.003,079.19% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K45.26N/AN/A$0.20 per share43.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableMNZS, MER, KGH, AIM, and OFX HeadlinesRecent News About These CompaniesAIM ImmunoTech (NYSE:AIM) & AlloVir (NASDAQ:ALVR) Critical ReviewJune 27 at 2:39 AM | americanbankingnews.comAIM ImmunoTech (NYSE:AIM) Shares Gap Up - Here's What HappenedJune 22, 2025 | americanbankingnews.comAIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity RequirementsJune 20, 2025 | finance.yahoo.comAIM ImmunoTech Faces NYSE Noncompliance NotificationJune 20, 2025 | tipranks.comAIM ImmunoTech Inc. Receives NYSE American Compliance Warning and Plans to Regain Compliance by June 2026June 20, 2025 | quiverquant.comQAIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity RequirementsJune 20, 2025 | globenewswire.comAIM ImmunoTech (NYSE:AIM) Shares Gap Up - Should You Buy?June 20, 2025 | marketbeat.comAIM ImmunoTech (NYSE:AIM) Trading Down 15.5% - Time to Sell?June 18, 2025 | marketbeat.comAIM ImmunoTech (NYSE:AIM) Sets New 1-Year High - Here's WhyJune 17, 2025 | marketbeat.comAIM ImmunoTech Inc. Common Stock Resumes Trading on NYSE AmericanJune 17, 2025 | quiverquant.comQAIM ImmunoTech Resumes Trading on NYSE AmericanJune 17, 2025 | globenewswire.comNostra Terra shares tipped for +300% upsideJune 16, 2025 | proactiveinvestors.co.ukSeeing Machines lands deal with ‘autonomous driving car company'June 16, 2025 | proactiveinvestors.co.ukAIM ImmunoTech granted U.S. patent for AmpligenJune 12, 2025 | msn.comAIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®June 12, 2025 | globenewswire.comAIM ImmunoTech Announces NYSE American Removal of Trading SuspensionJune 12, 2025 | globenewswire.comAIM ImmunoTech Inc.: AIM ImmunoTech Announces 1-for-100 Reverse Stock SplitJune 12, 2025 | finanznachrichten.deAIM ImmunoTech Announces 1-for-100 Reverse Stock SplitJune 11, 2025 | globenewswire.comAIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of ImmunologistsMay 8, 2025 | globenewswire.comZephyr Energy reports strong flow rates at Utah well, boosting Paradox project prospectsMay 7, 2025 | proactiveinvestors.co.ukMirriad shares crash 78% as cash crisis puts survival in doubtMay 1, 2025 | proactiveinvestors.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated3 Reasons AMD Could Be the Hottest Stock of the SummerBy Sam Quirke | June 20, 2025View 3 Reasons AMD Could Be the Hottest Stock of the SummerArcher's Midnight Air Taxi Soars, But Stock Doesn’t BudgeBy Jeffrey Neal Johnson | June 4, 2025View Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge3 Notable Stocks Just Split: Which One Could Be the Big Winner?By Leo Miller | June 26, 2025View 3 Notable Stocks Just Split: Which One Could Be the Big Winner?As Oil Prices Rebound, These Stocks Could Fuel the Next RallyBy Sarah Horvath | June 9, 2025View As Oil Prices Rebound, These Stocks Could Fuel the Next RallyMNZS, MER, KGH, AIM, and OFX Company DescriptionsAIM ImmunoTech NYSE:AIM$8.65 -0.25 (-2.81%) As of 03:53 PM EasternAIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
